Overview
Group figures Q2/H1 2022
Statement of Comprehensive Income
Reconciliation Fresenius Group
Reconciliation Fresenius Medical Care
Reconciliation Kabi
Reconciliation Helios
Reconciliation Vamed
Reconciliation Corporate
Estimated Covid-19-effects
Basis for guidance
Statement of Financial Position
Statement of Cash Flow
Segment Reporting Q2
Segment Rporting H1
Sales by business segment
Sales by region
Contact
Fresenius SE & Co. KGaA
Investor Relations & Sustainability
+49 (0) 6172 608-2485
ir-fre@fresenius.com
SAFE HARBOR STATEMENT
This file contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this file.
This file is provided for convenience purposes only. Reliance shall only be placed on the published investor news and the figures contained therein.
Income
< back to overview
Statement of Comprehensive Income (IFRS, unaudited)
€ in millions Q2/2022 Q2/2021 Growth H1/2022 H1/2021 Growth
Sales 10,018 9,246 8% 19,738 18,230 8%
Costs of sales -7,340 -6,628 -11% -14,502 -13,154 -10%
Gross profit 2,678 2,618 2% 5,236 5,076 3%
Selling, general and administrative expenses -1,631 -1,400 -17% -3,108 -2,666 -17%
Research and development expenses -202 -197 -3% -381 -383 1%
Operating income (EBIT) 845 1,021 -17% 1,747 2,027 -14%
Interest result -116 -121 4% -234 -258 9%
Financial result -116 -121 4% -234 -258 9%
Income before income taxes 729 900 -19% 1,513 1,769 -14%
Income taxes -165 -192 14% -350 -390 10%
Net income 564 708 -20% 1,163 1,379 -16%
Less noncontrolling interests -181 -237 24% -367 -473 22%
Net income attributable to Fresenius SE & Co. KGaA1,2 450 475 -5% 913 911 0%
Net income attributable to Fresenius SE & Co. KGaA1 383 471 -19% 796 906 -12%
Earnings per ordinary share (€)1,2 0.80 0.85 -6% 1.63 1.63 0%
Fully diluted earnings per ordinary share (€)1,2 0.80 0.85 -6% 1.63 1.63 0%
Earnings per ordinary share (€)1 0.68 0.84 -19% 1.42 1.62 -12%
Fully diluted earnings per ordinary share (€)1 0.68 0.84 -19% 1.42 1.62 -12%
Average number of shares 560,080,521 557,771,093 0% 559,291,332 557,656,126 0%
EBITDA2 1,682 1,674 0% 3,344 3,305 1%
Depreciation and amortization2 679 641 6% 1,341 1,263 6%
EBIT2 1,003 1,033 -3% 2,003 2,042 -2%
EBITDA margin2 16.8% 18.1% 16.9% 18.1%
EBIT margin2 10.0% 11.2% 10.1% 11.2%
1 Net income attributable to Fresenius SE & Co. KGaA
2 Before special items
Reconciliation Group
< back to overview
Consolidated results for Q2/2022 and H1/2022 as well as for Q2/2021 and H1/2021 include special items. These concern: Revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program (including costs related to FME25 program), impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties as well as remeasurement Humacyte investment. The special items shown within the reconciliation tables are reported in the "Corporate" segment. Consolidated results for Q2/2022 and H1/2022 as well as for Q2/2021 and H1/2021 include special items. These concern: Revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program (including costs related to FME25 program), impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties as well as remeasurement Humacyte investment. The special items shown within the reconciliation tables are reported in the "Corporate" segment.
Fresenius Group Fresenius Group
€ in millions Q2/22 Q2/21 Growth rate Growth rate (cc) € in millions H1/22 H1/21 Growth rate Growth rate (cc)
Sales reported 10,018 9,246 8% 3% Sales reported 19,738 18,230 8% 4%
EBIT reported (after special items) 845 1,021 -17% -23% EBIT reported 1,747 2,027 -14% -18%
Revaluations of biosimilars contingent purchase price liabilities - - Revaluations of biosimilars contingent purchase price liabilities -2 -
Expenses associated with the Fresenius cost and efficiency program 50 12 Expenses associated with the Fresenius cost and efficiency program 114 15
Impacts related to the war in Ukraine 10 - Impacts related to the war in Ukraine 40 -
Transaction costs mAbxience, Ivenix 5 - Transaction costs mAbxience, Ivenix 7 -
Hyperinflation Turkey 10 - Hyperinflation Turkey 10 -
Retroactive duties 9 - Retroactive duties 9 -
Remeasurement Humacyte investment 74 - Remeasurement Humacyte investment 78 -
EBIT (before special items) 1,003 1,033 -3% -9% EBIT (before special items) 2,003 2,042 -2% -7%
Net interest reported (after special items) -116 -121 4% 10% Net interest reported -234 -258 9% 14%
Revaluations of biosimilars contingent purchase price liabilities - - Revaluations of biosimilars contingent purchase price liabilities -1 -
Net interest (before special items) -116 -121 4% 10% Net interest (before special items) -235 -258 9% 13%
Income taxes reported (after special items) -165 -192 14% 19% Income taxes reported (after special items) -350 -390 10% 14%
Revaluations of biosimilars contingent purchase price liabilities - - Revaluations of biosimilars contingent purchase price liabilities 1 -
Expenses associated with the Fresenius cost and efficiency program -14 -4 Expenses associated with the Fresenius cost and efficiency program -26 -5
Impacts related to the war in Ukraine -1 - Impacts related to the war in Ukraine -4 -
Transaction costs mAbxience, Ivenix -1 - Transaction costs mAbxience, Ivenix -1 -
Hyperinflation Turkey 0 - Hyperinflation Turkey 0 -
Retroactive duties -3 - Retroactive duties -3 -
Remeasurement Humacyte investment -20 - Remeasurement Humacyte investment -21 -
Income taxes (before special items) -204 -196 -4% 3% Income taxes (before special items) -404 -395 -2% 3%
Noncontrolling interests reported (after special items) -181 -237 24% 32% Noncontrolling interests reported (after special items) -367 -473 22% 28%
Expenses associated with the Fresenius cost and efficiency program -9 -4 Expenses associated with the Fresenius cost and efficiency program -26 -5
Impacts related to the war in Ukraine -3 - Impacts related to the war in Ukraine -16 -
Hyperinflation Turkey -4 - Hyperinflation Turkey -4 -
Remeasurement Humacyte investment -36 - Remeasurement Humacyte investment -38 -
Noncontrolling interests (before special items) -233 -241 3% 12% Noncontrolling interests (before special items) -451 -478 6% 12%
Net income reported (after special items)1 383 471 -19% -24% Net income reported (after special items)1 796 906 -12% -16%
Revaluations of biosimilars contingent purchase price liabilities - - Revaluations of biosimilars contingent purchase price liabilities -2 -
Expenses associated with the Fresenius cost and efficiency program 27 4 Expenses associated with the Fresenius cost and efficiency program 62 5
Impacts related to the war in Ukraine 6 - Impacts related to the war in Ukraine 20 -
Transaction costs mAbxience, Ivenix 4 - Transaction costs mAbxience, Ivenix 6 -
Hyperinflation Turkey 6 - Hyperinflation Turkey 6 -
Retroactive duties 6 - Retroactive duties 6 -
Remeasurement Humacyte investment 18 - Remeasurement Humacyte investment 19 -
Net income (before special items)1 450 475 -5% -10% Net income (before special items)1 913 911 0% -4%
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Reconciliation FMC
< back to overview
Fresenius Medical Care Fresenius Medical Care
in € millions Q2/22 Q2/21 Growth rate Growth rate (cc) in € millions H1/22 H1/21 Growth rate Growth rate (cc)
Sales reported 4,757 4,320 10% 1% Sales reported 9,305 8,530 9% 2%
EBIT reported (after special items) 341 424 -20% -27% EBIT reported (after special items) 688 898 -23% -29%
Costs related to FME25 program 21 9 Costs related to FME25 program 57 12
Impacts related to the war in Ukraine 2 - Impacts related to the war in Ukraine 23 -
Hyperinflation Turkey 6 - Hyperinflation Turkey 6 -
Remeasurement Humacyte investment 75 - Remeasurement Humacyte investment 78 -
EBIT (before special items) 445 433 3% -6% EBIT (before special items) 852 910 -6% -13%
Net income reported (after special items)1 147 219 -33% -39% Net income reported (after special items)1 305 468 -35% -39%
Costs related to FME25 program 15 6 Costs related to FME25 program 40 8
Impacts related to the war in Ukraine 2 - Impacts related to the war in Ukraine 20 -
Hyperinflation Turkey 6 - Hyperinflation Turkey 6 -
Remeasurement Humacyte investment 55 - Remeasurement Humacyte investment 57 -
Net income (before special items)1 225 225 0% -7% Net income (before special items)1 428 476 -10% -15%
1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA 1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
Reconciliation Kabi
< back to overview
Fresenius Kabi Fresenius Kabi
€ in millions Q2/22 Q2/21 Growth rate Growth rate (cc) € in millions H1/22 H1/21 Growth rate Growth rate (cc)
Sales reported 1,896 1,755 8% 2% Sales reported 3,743 3,516 6% 1%
Revaluations of biosimilars contingent purchase price liabilities - - Revaluations of biosimilars contingent purchase price liabilities -2 -
Expenses associated with the Fresenius cost and efficiency program 18 - Expenses associated with the Fresenius cost and efficiency program 46 -
Impacts related to the war in Ukraine 4 - Impacts related to the war in Ukraine 12 -
Transaction costs mAbxience, Ivenix 5 - Transaction costs mAbxience, Ivenix 7 -
Hyperinflation Turkey 4 - Hyperinflation Turkey 4 -
EBIT (before special items) 271 298 -9% -17% EBIT (before special items) 564 574 -2% -9%
Reconciliation Helios
< back to overview
Fresenius Helios Fresenius Helios
€ in millions Q2/22 Q2/21 Growth rate Growth rate (cc) € in millions H1/22 H1/21 Growth rate Growth rate (cc)
Sales reported 2,925 2,738 7% 6% Sales reported 5,856 5,387 9% 8%
EBIT reported (after special items) 303 298 2% 1% EBIT reported (after special items) 609 566 8% 7%
Expenses associated with the Fresenius cost and efficiency program 0 - Expenses associated with the Fresenius cost and efficiency program 0 -
EBIT (before special items) 303 298 2% 1% EBIT (before special items) 609 566 8% 7%
Reconciliation Vamed
< back to overview
Fresenius Helios Fresenius Helios
€ in millions Q2/22 Q2/21 Growth rate Growth rate (cc) € in millions H1/22 H1/21 Growth rate Growth rate (cc)
Sales reported 562 556 1% 1% Sales reported 1,075 1,033 4% 3%
EBIT reported (after special items) 5 16 -69% -69% EBIT reported (after special items) 12 12 0% 0%
Expenses associated with the Fresenius cost and efficiency program 1 - Expenses associated with the Fresenius cost and efficiency program 2 -
Impacts related to the war in Ukraine 5 - Impacts related to the war in Ukraine 5 -
EBIT (before special items) 11 16 -31% -31% EBIT (before special items) 19 12 58% 58%
Reconciliation Corporate
< back to overview
Fresenius Corporate Fresenius Corporate
€ in millions Q2/22 Q2/21 Growth rate Growth rate (cc) € in millions H1/22 H1/21 Growth rate Growth rate (cc)
Expenses associated with the Fresenius cost and efficiency program 7 3 Expenses associated with the Fresenius cost and efficiency program 9 3
Retroactive duties 9 - Retroactive duties 9 -
EBIT (before special items) -27 -12 -125% -125% EBIT (before special items) -41 -20 -105% -110%
Covid-19-effects
< back to overview
Estimated COVID-19 effects Q2/2021
Growth cc Estimated Estimated Growth cc
as reported COVID impact cc
incl. COVID-19 excl. COVID-19
€m Q2/22 Q2/21 Q2/22 Q2/21 Q2/22 Q2/21
Sales 3% 8% 1% to 0% 2% to 1% 2% to 3% 6% to 7%
Net income before special items1 -10% 20% 6% to 2% 10% to 6% -16% to -12% 10% to 14%
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Estimated COVID-19 effects H1/2021
Growth cc Estimated Estimated Growth cc
as reported COVID impact cc
incl. COVID-19 excl. COVID-19
€m H1/22 H1/21 H1/22 H1/21 H1/22 H1/21
Sales 4% 6% 0% to -1% 1% to 0% 4% to 5% 5% to 6%
Net income before special items1 -4% 8% 6% to 2% 4% to 0% -10% to -6% 4% to 8%
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Basis for guidance
< back to overview
Fresenius Group/ Fresenius Medical Care / Fresenius Kabi / Fresenius Helios / Fresenius Vamed
Base for Guidance 2022
€ in millions Fresenius Group Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed
Sales reported (base) 37,520 17,619 7,193 10,891 2,297
Revaluations of biosimilars contingent purchase price liabilities -49
Expenses associated with the Fresenius cost and efficiency program 58 10 0
EBIT (before special items) = base Kabi, Helios, Vamed guidance 1,153 1,127 101
Net income (as reported) 1,818 969
Revaluations of biosimilars contingent purchase price liabilities -33
Costs related to FME25 program 49
Expenses associated with the Fresenius cost and efficiency program 82
Net income (before special items) = base FMC guidance 1,018
Net income (before special items) = base Fresenius Group guidance 1,867
Balance sheet
< back to overview
€ in millions June 30, 2022 December 31, 2021 Change
Assets
Current assets 18,818 17,461 8%
thereof trade accounts receivables 7,858 7,045 12%
thereof inventories 4,697 4,218 11%
thereof cash and cash equivalents 2,129 2,764 -23%
Non-current assets 57,294 54,501 5%
thereof property, plant and equipment 12,943 12,569 3%
thereof goodwill and other intangible assets 34,935 32,774 7%
thereof right-of-use-assets 6,238 6,014 4%
Total assets 76,112 71,962 6%
Liabilities and shareholders' equity
Liabilities 44,079 42,674 3%
thereof trade accounts payable 1,929 2,039 -5%
thereof accruals and other short-term liabilities 10,542 10,594 0%
thereof debt 28,368 27,155 4%
thereof lease liabilities 6,858 6,590 4%
Noncontrolling interests 11,369 10,290 10%
Total Fresenius SE & Co. KGaA shareholders' equity 20,664 18,998 9%
Total shareholders' equity 32,033 29,288 9%
Total liabilities and shareholders' equity 76,112 71,962 6%
Cash Flow
< back to overview
Statement of Cash Flows (IFRS, unaudited)
€ in millions Q2/2022 Q2/2021 Growth H1/2022 H1/2021 Growth
Net income 564 708 -20% 1,163 1,379 -16%
Depreciation and amortization 683 641 7% 1,376 1,263 9%
Change in working capital and others -230 102 -- -1,421 -539 -164%
Operating cash flow 1,017 1,451 -30% 1,118 2,103 -47%
Capital expenditure, net -436 -499 13% -792 -910 13%
Cash flow before acquisitions and dividends 581 952 -39% 326 1,193 -73%
Cash used for acquisitions, net -271 -456 41% -363 -519 30%
Dividends paid -701 -855 18% -757 -916 17%
Free cash flow after acquisitions and dividends -391 -359 -9% -794 -242 --
Cash provided by/used for financing activities 408 711 -43% 89 588 -85%
Effect of exchange rates on change in cash and cash equivalents 35 21 67% 70 67 4%
Net change in cash and cash equivalents 52 373 -86% -635 413 --
Segment Reporting Q2
< back to overview
Segment reporting by business unit Q2/2022 (IFRS, unaudited)
Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate Fresenius Group
€ in millions Q2/22 1 Q2/21 2 Growth Q2/22 3 Q2/21 Growth Q2/22 4 Q2/21 Growth Q2/22 5 Q2/21 Growth Q2/22 6 Q2/21 7 Growth Q2/22 Q2/21 Growth
Sales 4,757 4,320 10% 1,896 1,755 8% 2,925 2,738 7% 562 556 1% -122 -123 1% 10,018 9,246 8%
thereof contribution to consolidated sales 4,740 4,308 10% 1,878 1,739 8% 2,918 2,732 7% 481 466 3% 1 1 0% 10,018 9,246 8%
thereof intercompany sales 17 12 42% 18 16 13% 7 6 17% 81 90 -10% -123 -124 1% - -
contribution to consolidated sales 47% 47% 19% 19% 29% 29% 5% 5% 0% 0% 100% 100%
EBITDA 866 829 5% 379 406 -7% 429 413 4% 35 38 -8% -181 -24 -- 1,528 1,662 -8%
Depreciation and amortization 421 396 7% 108 108 0% 126 115 10% 24 22 9% 4 0 -- 683 641 7%
EBIT 445 433 3% 271 298 -9% 303 298 2% 11 16 -31% -185 -24 -- 845 1,021 -17%
Net interest -72 -69 -3% -9 -16 44% -45 -45 0% -1 -1 0% 11 10 10% -116 -121 4%
Income taxes -91 -77 -15% -58 -59 2% -57 -54 -6% -3 -3 0% 44 1 -- -165 -192 14%
Net income attributable to shareholders of Fresenius SE & Co. KGaA 225 225 0% 189 204 -7% 197 193 2% 6 11 -45% -234 -162 -44% 383 471 -19%
Operating cash flow 751 921 -18% 109 197 -45% 194 223 -13% 7 58 -88% -44 52 -185% 1,017 1,451 -30%
Cash flow before acquisitions and dividends 582 720 -19% -1 83 -101% 48 70 -31% -2 33 -106% -46 46 -200% 581 952 -39%
Capital expenditure 172 210 -18% 102 117 -13% 134 154 -13% 8 25 -68% 3 3 0% 419 509 -18%
Acquisitions 67 79 -14% 220 - 3 412 -99% - 0 -100% 1 - 291 491 -41%
Research and development expenses 55 52 7% 147 144 2% 1 1 0% - - -1 0 -- 202 197 3%
Key figures
EBITDA margin 18.2% 19.2% 20.0% 23.1% 14.7% 15.1% 6.2% 6.8% 16.8% 8 18.1% 4
EBIT margin 9.4% 10.0% 14.3% 17.0% 10.4% 10.9% 2.0% 2.9% 10.0% 8 11.2% 4
Depreciation and amortization in % of sales 8.9% 9.2% 5.7% 6.2% 4.3% 4.2% 4.3% 4.0% 6.8% 6.9%
Operating cash flow in % of sales 15.8% 21.3% 5.7% 11.2% 6.6% 8.1% 1.2% 10.4% 10.2% 15.7%
1 Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey and remeasurement Humacyte investment
2 Before costs related to FME25 program
3 Before expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey
4 Before expenses associated with the Fresenius cost and efficiency program
5 Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine
6 After expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
7 After expenses associated with the Fresenius cost and efficiency program
8 Before expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
Segment Reporting H1
< back to overview
Segment reporting by business unit H1/2022 (IFRS, unaudited)
Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate Fresenius Group
€ in millions H1/22 2 H1/21 3 Growth H1/22 4 H1/21 Growth H1/22 5 H1/21 Growth H1/22 6 H1/21 Growth H1/22 7 H1/21 8 Growth H1/22 H1/21 Growth
Sales 9,305 8,530 9% 3,743 3,516 6% 5,856 5,387 9% 1,075 1,033 4% -241 -236 -2% 19,738 18,230 8%
thereof contribution to consolidated sales 9,274 8,507 9% 3,707 3,484 6% 5,844 5,375 9% 912 863 6% 1 1 0% 19,738 18,230 8%
thereof intercompany sales 31 23 35% 36 32 13% 12 12 0% 163 170 -4% -242 -237 -2% - -
contribution to consolidated sales 47% 47% 19% 19% 29% 29% 5% 5% 0% 0% 100% 100%
EBITDA 1,686 1,694 0% 775 780 -1% 857 793 8% 67 55 22% -262 -32 -- 3,123 3,290 -5%
Depreciation and amortization 834 784 6% 211 206 2% 248 227 9% 48 43 12% 35 3 -- 1,376 1,263 9%
EBIT 852 910 -6% 564 574 -2% 609 566 8% 19 12 58% -297 -35 -- 1,747 2,027 -14%
Net interest -141 -145 3% -20 -33 39% -93 -89 -4% -3 -4 25% 23 13 77% -234 -258 9%
Income taxes -171 -172 2% -120 -118 -2% -115 -102 -13% -4 -2 -100% 60 4 -- -350 -390 10%
Net income attributable to shareholders of Fresenius SE & Co. KGaA 428 476 -10% 390 394 -1% 392 366 7% 10 4 150% -424 -334 -27% 796 906 -12%
Operating cash flow 910 1,129 -19% 242 475 -49% 58 438 -87% -38 14 -- -54 47 -- 1,118 2,103 -47%
Cash flow before acquisitions and dividends 581 749 -22% 38 229 -83% -179 208 -186% -56 -33 -70% -58 40 -- 326 1,193 -73%
Total assets1 36,070 34,367 5% 15,855 14,698 8% 21,593 20,891 3% 2,906 2,795 4% -312 -789 60% 76,112 71,962 6%
Debt1 13,659 13,320 3% 4,346 4,159 4% 8,214 8,059 2% 830 721 15% 1,319 896 47% 28,368 27,155 4%
Other operating liabilities1 6,024 6,199 -3% 3,386 3,250 4% 3,406 3,176 7% 1,009 994 2% 118 385 -69% 13,943 14,004 0%
Capital expenditure 334 394 -15% 186 216 -14% 213 230 -7% 20 47 -57% 4 6 -33% 757 893 -15%
Acquisitions 150 210 -28% 222 1 -- 75 429 -83% 6 0 -- - - 453 640 -29%
Research and development expenses 105 101 4% 275 281 -2% 1 2 -50% - - 0 -1 100% 381 383 -1%
Employees (per capita on balance sheet date)1 130,448 130,251 0% 42,186 41,397 2% 125,101 123,484 1% 19,781 19,721 0% 1,131 1,225 -8% 318,647 316,078 1%
Key figures
EBITDA margin 18.1% 19.9% 20.7% 22.2% 14.6% 14.7% 6.2% 5.3% 16.9% 9 18.1% 5
EBIT margin 9.2% 10.7% 15.1% 16.3% 10.4% 10.5% 1.8% 1.2% 10.1% 9 11.2% 5
Depreciation and amortization in % of sales 9.0% 9.2% 5.6% 5.9% 4.2% 4.2% 4.5% 4.2% 7.0% 6.9%
Operating cash flow in % of sales 9.8% 13.2% 6.5% 13.5% 1.0% 8.1% -3.5% 1.4% 5.7% 11.5%
ROOA1 5.5% 6.2% 8.7% 9.4% 5.9% 5.9% 4.4% 4.3% 6.1% 10 6.5% 11
1 2021: December 31
2 Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey and remeasurement Humacyte investment
3 Before costs related to FME25 program
4 Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey
5 Before expenses associated with the Fresenius cost and efficiency program
6 Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine
7 After revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
8 After expenses associated with the Fresenius cost and efficiency program
9 Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
10 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment.
11 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities and expenses associated with the Fresenius cost and efficiency program.
Sales by business segment
< back to overview
Sales by business segment
€ in millions Q2/22 Q2/21 Growth Currency translation effects Growth at constant rates Organic sales growth Acquisitions Divestitures/Others % of total sales1
Fresenius Medical Care 4,757 4,320 10% 9% 1% 0% 1% 0% 47%
Fresenius Kabi 1,896 1,755 8% 6% 2% 2% 0% 0% 19%
Fresenius Helios 2,925 2,738 7% 1% 6% 5% 1% 0% 29%
Fresenius Vamed 562 556 1% 0% 1% 1% 1% -1% 5%
Total 10,018 9,246 8% 5% 3% 2% 1% 0% 100%
1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.
€ in millions H1/22 H1/21 Growth Currency translation effects Growth at constant rates Organic sales growth Acquisitions Divestitures/Others % of total sales1
Fresenius Medical Care 9,305 8,530 9% 7% 2% 1% 1% 0% 47%
Fresenius Kabi 3,743 3,516 6% 5% 1% 1% 0% 0% 19%
Fresenius Helios 5,856 5,387 9% 1% 8% 6% 2% 0% 29%
Fresenius Vamed 1,075 1,033 4% 1% 3% 4% 0% -1% 5%
Total 19,738 18,230 8% 4% 4% 3% 1% 0% 100%
1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.
Sales by region
< back to overview
Sales by region
€ in millions Q2/22 Q2/21 Growth Currency translation effects Growth at constant rates Organic growth Acquisitions Divestitures/Others % of total sales
North America 3,916 3,486 12% 13% -1% -1% 1% -1% 39%
Europe 4,430 4,229 5% 0% 5% 4% 1% -0% 44%
Asia-Pacific 1,004 961 4% 6% -2% -2% 0% 0% 10%
Latin America 531 453 17% 7% 10% 8% 2% 0% 5%
Africa 137 117 17% 0% 17% 17% 0% 0% 2%
Total 10,018 9,246 8% 5% 3% 2% 1% 0% 100%
€ in millions H1/22 H1/21 Growth Currency translation effects Growth at constant rates Organic growth Acquisitions Divestitures/Others % of total sales
North America 7,675 6,929 11% 10% 1% -1% 1% 1% 39%
Europe 8,811 8,340 6% 0% 6% 5% 1% -0% 45%
Asia-Pacific 2,008 1,881 7% 6% 1% 1% 0% 0% 10%
Latin America 1,003 875 15% 5% 10% 8% 2% 0% 5%
Africa 241 205 18% 2% 16% 16% 0% 0% 1%
Total 19,738 18,230 8% 4% 4% 3% 1% 0% 100%

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 02 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2022 06:29:02 UTC.